HC Wainwright Predicts Nkarta’s Q3 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Nkarta in a research note issued on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.46) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.57) EPS and FY2030 earnings at ($1.36) EPS.

Several other research analysts also recently commented on NKTX. Wall Street Zen downgraded Nkarta from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Stifel Nicolaus lowered their price objective on Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nkarta has an average rating of “Moderate Buy” and an average target price of $11.20.

Nkarta Price Performance

Shares of NASDAQ NKTX opened at $1.53 on Wednesday. The company has a 50 day simple moving average of $2.40 and a 200 day simple moving average of $2.52. The firm has a market cap of $109.58 million, a PE ratio of -0.97 and a beta of 1.24. Nkarta has a 1 year low of $1.48 and a 1 year high of $3.72.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.18).

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NKTX. BlackRock Inc. acquired a new stake in shares of Nkarta during the 2nd quarter worth approximately $17,830,000. Monaco Asset Management SAM bought a new stake in shares of Nkarta in the 2nd quarter valued at $6,717,000. Renaissance Technologies LLC lifted its position in shares of Nkarta by 1.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,732,372 shares of the company’s stock valued at $3,655,000 after acquiring an additional 30,350 shares during the period. AWM Investment Company Inc. acquired a new position in shares of Nkarta during the 2nd quarter valued at $2,564,000. Finally, Dimensional Fund Advisors LP boosted its stake in Nkarta by 74.4% during the first quarter. Dimensional Fund Advisors LP now owns 346,593 shares of the company’s stock worth $731,000 after acquiring an additional 147,894 shares in the last quarter. 80.54% of the stock is owned by institutional investors.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.